279 related articles for article (PubMed ID: 15327418)
21. Improving long-term outcomes in idiopathic membranous nephropathy using a distinctive cyclosporine regimen.
Hassan K; Kristal B
Minerva Urol Nefrol; 2016 Jun; 68(3):293-301. PubMed ID: 25645342
[TBL] [Abstract][Full Text] [Related]
22. Remissions and relapses in idiopathic membranous nephropathy.
Ponticelli C; Passerini P; Altieri P; Locatelli F; Pappalettera M
Nephrol Dial Transplant; 1992; 7 Suppl 1():85-90. PubMed ID: 1337188
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcome of patients with idiopathic membranous nephropathy.
Ríhová Z; Merta M; Maixnerová D; Honsová E; Reiterová J; Rysavá R; Zabka J; Tesar V
Prague Med Rep; 2006; 107(2):189-98. PubMed ID: 17066739
[TBL] [Abstract][Full Text] [Related]
24. Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study.
van de Logt AE; Beerenhout CH; Brink HS; van de Kerkhof JJ; Wetzels JF; Hofstra JM
PLoS One; 2015; 10(11):e0142033. PubMed ID: 26562836
[TBL] [Abstract][Full Text] [Related]
25. Have we changed the outcome in membranous nephropathy? A propensity study on the role of immunosuppressive therapy.
Cattran DC; Reich HN; Kim SJ; Troyanov S
Clin J Am Soc Nephrol; 2011 Jul; 6(7):1591-8. PubMed ID: 21685024
[TBL] [Abstract][Full Text] [Related]
26. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial.
Praga M; Barrio V; Juárez GF; Luño J;
Kidney Int; 2007 May; 71(9):924-30. PubMed ID: 17377504
[TBL] [Abstract][Full Text] [Related]
27. Early initiation of immunosuppressive treatment in membranous nephropathy patients.
Chan CK; Lai TS; Chen PM; Chou YH; Wu CF; Chiu YL; Chiang WC; Chen YM; Chu TS; Wu KD
J Formos Med Assoc; 2017 Apr; 116(4):266-275. PubMed ID: 28202222
[TBL] [Abstract][Full Text] [Related]
28. Cyclosporine treatment in idiopathic membranous nephropathy nephrotic syndrome in adults: a retrospective study spanning 15 years.
Tao JL; Liu LL; Wen YB; Gao RT; Li H; Li MX; Li XM; Li XW
Chin Med J (Engl); 2011 Nov; 124(21):3490-4. PubMed ID: 22340164
[TBL] [Abstract][Full Text] [Related]
29. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs.
Goumenos DS; Katopodis KP; Passadakis P; Vardaki E; Liakopoulos V; Dafnis E; Stefanidis I; Vargemezis V; Vlachojannis JG; Siamopoulos KC
Am J Nephrol; 2007; 27(3):226-31. PubMed ID: 17389782
[TBL] [Abstract][Full Text] [Related]
30. [The late results of treating membranous glomerulonephritis].
Belovezhdov N; Robeva R; Dimitrova V
Vutr Boles; 1990; 29(3):53-60. PubMed ID: 2284800
[TBL] [Abstract][Full Text] [Related]
31. Spontaneous remission of nephrotic syndrome in membranous nephropathy with chronic renal impairment.
Polanco N; Gutiérrez E; Rivera F; Castellanos I; Baltar J; Lorenzo D; Praga M;
Nephrol Dial Transplant; 2012 Jan; 27(1):231-4. PubMed ID: 21624942
[TBL] [Abstract][Full Text] [Related]
32. Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy.
Laluck BJ; Cattran DC
Am J Kidney Dis; 1999 Jun; 33(6):1026-32. PubMed ID: 10352189
[TBL] [Abstract][Full Text] [Related]
33. Prediction in idiopathic membranous nephropathy.
Marx BE; Marx M
Kidney Int; 1999 Aug; 56(2):666-73. PubMed ID: 10432407
[TBL] [Abstract][Full Text] [Related]
34. Benefit and cost from the long-term use of cyclosporine-A in idiopathic membranous nephropathy.
Kalliakmani P; Koutroulia E; Sotsiou F; Vlachojannis JG; Goumenos DS
Nephrology (Carlton); 2010 Dec; 15(8):762-7. PubMed ID: 21175962
[TBL] [Abstract][Full Text] [Related]
35. Prognosis of untreated patients with idiopathic membranous nephropathy.
Schieppati A; Mosconi L; Perna A; Mecca G; Bertani T; Garattini S; Remuzzi G
N Engl J Med; 1993 Jul; 329(2):85-9. PubMed ID: 8510707
[TBL] [Abstract][Full Text] [Related]
36. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcomes of persistent disease and relapse in primary membranous nephropathy.
Kanigicherla DA; Short CD; Roberts SA; Hamilton P; Nikam M; Harris S; Brenchley PE; Venning MC
Nephrol Dial Transplant; 2016 Dec; 31(12):2108-2114. PubMed ID: 26769682
[TBL] [Abstract][Full Text] [Related]
38. Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy.
Hofstra JM; Deegens JK; Willems HL; Wetzels JF
Nephrol Dial Transplant; 2008 Aug; 23(8):2546-51. PubMed ID: 18308774
[TBL] [Abstract][Full Text] [Related]
39. Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety.
Yang S; Xie L; Xue W; Yin A; Lu W
Nephrology (Carlton); 2013 Sep; 18(9):615-22. PubMed ID: 23889815
[TBL] [Abstract][Full Text] [Related]
40. Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria.
Li X; Lv R; He Q; Li H; Du X; Lin W; Li Q; He X; Wang S; Chen J
J Nephrol; 2008; 21(4):584-91. PubMed ID: 18651550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
